Search Results 501-510 of 18379 for alopecia

1. Phase I Study Of BL0020, A Novel Anti-tumor Drug, In Adult Subjects With Advanced Solid Tumors - Mayo Clinic

   ... alopecia) have not been recovered. 20. Patients who are taking anticoagulant therapy (prophylactic use of low-dose aspirin \[≤ 100 mg/day\] or low ...

2. A Study of Response, Survival, Safety, and Tolerability of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer - Mayo Clinic

   ... alopecia, and irreversible late sequelae of radiation therapy, must have resolved to Grade 0 or 1 per Common Terminology Criteria for Adverse Events (CTCAE ...

3. A Study to Compare Docetaxel/Prednisone to Docetaxel/Prednisone Combined with OGX-011 in Men with Prostate Cancer - Mayo Clinic

   ... alopecia, anemia and any signs or symptoms of androgen deprivation therapy; Must be willing to not add, delete or change their current bisphosphonate or ...

4. Publications - Tufia C. Haddad, M.D. - Mayo Clinic

   ... alopecia in breast cancer. Support Care Cancer. 2024 Jun 6; 32 (7):412 Epub 2024 June 06. View PubMed; Haemmerle R, Paludo J, Haddad TC, Pritchett JC. The ...

5. Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer - Mayo Clinic

   Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diverticulosis, diabetes mellitus type I, vitiligo, alopecia, psoriasis ...

6. A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma - Mayo Clinic

   0, except for alopecia. Patients with chronic but stable Grade 2 toxicities may be allowed to enroll after an agreement between the Investigator and Sponsor ...

7. A Study to Evaluate T-DM1 With or Without Abemaciclib in Women and Men with HER2-positive Advanced or Metastatic Breast Cancer - Mayo Clinic

   NOTE: All residual toxicities (except alopecia) should be at baseline or grade 1 (including peripheral neuropathy). NOTE: If indicated, patients can ...

8. A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma - Mayo Clinic

   Resolution of all acute adverse events resulting from prior cancer therapies to NCI CTCAE grade ≤ 1 or baseline (except alopecia); Adequate organ function ...

9. Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer - Mayo Clinic

   ... alopecia and peripheral neuropathy. Have adequate organ function, including: Hematologic: absolute neutrophil count ≥1.5 × 10⁹/Liter (L), platelets ≥100 ...

10. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies - Mayo Clinic

    Participation eligibility · Exceptions: Neuropathy, fatigue, and/or alopecia may be Grade 1. · Known active central nervous system (CNS) metastases. NOTE: ...